Supernus Pharmaceuticals (SUPN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stacy Ku from TD Cowen maintained a Buy rating on the stock and has a $44.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Stacy Ku’s rating is based on several factors that highlight the potential growth and strategic positioning of Supernus Pharmaceuticals. The company reported a first-quarter revenue of approximately $149.8 million, which was slightly above consensus expectations. Despite a quarterly decline, the management’s guidance for 2025 indicates a revenue range of $600-630 million, showcasing a promising growth trajectory excluding the impact of Trokendi and Oxtellar.
A significant factor in the Buy rating is the performance and future potential of Qelbree, a key product for Supernus. Although Qelbree’s first-quarter sales were slightly below expectations, the management anticipates improvements in the upcoming quarters. The product’s unique mechanism of action and positive clinician feedback suggest a strong market potential, particularly in the adult ADHD segment. The expectation that Qelbree could capture a significant share of the ADHD market further supports the optimistic outlook for Supernus Pharmaceuticals.